InflaRx Prepares for Key Financial Results Release InflaRx is set to release its full-year 2024 financial results on March 20, 2025. The company, specializing in anti-inflammatory therapeutics, will also participate in two investor conferences this month. With a focus on C5a inhibitors, InflaRx continues to advance its pipeline, including vilobelimab and INF904.3